Dexcom Inc
NASDAQ:DXCM
Net Margin
Dexcom Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
32.3B USD |
13%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
222.9B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
175.2B USD |
29%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
156.4B USD |
14%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
152.3B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
117.1B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
53B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
51.8B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.6B USD |
73%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
43.7B USD |
23%
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
40.6B USD |
26%
|
Dexcom Inc
Glance View
Dexcom Inc. emerged as a pioneering force in the realm of continuous glucose monitoring (CGM), redefining the landscape of diabetes management. Founded in 1999, this San Diego-based company disrupted traditional blood glucose monitoring with its innovative technology, allowing individuals to track glucose levels in real-time without frequent finger-pricking. The company’s CGM systems, such as the G6 model, utilize a small sensor inserted beneath the skin that transmits data to a wearable device or smartphone, allowing patients and healthcare providers a comprehensive view of glucose trends. This approach empowers users with critical information for better diabetes management, reducing the likelihood of complications resulting from high or low blood sugar. Dexcom’s revenue generation revolves around the sales of its CGM systems, sensors, and related software services. By selling the initial monitoring devices and disposable sensors that typically need to be replaced every ten days, the company ensures a steady, recurring revenue stream. Furthermore, its integration with healthcare providers and insurers broadens its reach, tapping into a vast network of patients worldwide. Dexcom also collaborates with tech giants to enhance interoperability and data analytics, thereby embedding its solutions in broader digital health ecosystems. As diabetes continues to be a growing global concern, Dexcom’s strategic focus on innovation and strategic partnerships positions it as a leader in the CGM market.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Dexcom Inc's most recent financial statements, the company has Net Margin of 12.9%.
You don't have any saved screeners yet